Purpose We conducted a phase I study of hepatic arterial infusion (HAI) cisplatin and systemic chemotherapy in patients with advanced cancer and dominant liver involvement. Methods Patients were treated with HAI cisplatin 100-125 mg/m 2 (and 3,000 IU heparin) intraarterially and liposomal doxorubicin (doxil) 20-35 mg/m 2 IV (day 1) every 28 days. A "3 + 3" study design was used. Results Thirty patients were treated (median age, 56 years). Diagnoses were breast cancer (n = 11), colorectal cancer (n = 8), ocular melanoma (n = 4), and other (n = 7). The median number of prior therapies was 5. The maximum tolerated dose (MTD) was at the 100/35 mg/m 2 level. Dose-limiting toxicities were Grade 4 neutropenia (2 of 4 patients), and Grade 4 thrombocytopenia (n = 1) at the cisplatin 125 mg/m 2 and systemic doxil 35 mg/m 2 dose level. The most common toxicities were nausea/vomiting and fatigue. Of 24 patients evaluable for response, 4 (17%) had a partial response (PR) and 7 (29%) had stable disease (SD) for ¸4 months. Of the 11 patients with breast cancer, 3 (27%) had a PR and 5 (45%) had SD for ¸4 months. Of 4 patients with ocular melanoma, 1 had a PR and 1 SD for 4 months. One patient with hepatocellular carcinoma had SD for 4 months. Of 12 evaluable patients treated at the MTD, 2 (17%) had a PR and 5 (42%) had SD. Conclusion The MTD was HAI cisplatin 100 mg/m 2 and systemic doxil 35 mg/m 2 . This regimen demonstrated antitumor activity, especially in breast cancer.
Introduction
Liver metastases from solid tumors are associated with a poor prognosis.
Overall, 15-25% of patients with colorectal cancer present with liver metastases, and another 25-50% develop hepatic metastasis following resection of the primary tumor [1] [2] [3] .
Approximately 85% of patients with metastatic ocular melanoma have liver involvement, and in half of these patients the metastatic tumor is limited to the liver [4] .melanoma to the liver, resection or radiofrequency ablation of liver metastasis is rarely possible because of multifocal involvement of the liver in these patients [5] .
Although resection of liver metastases from colorectal cancer can produce long-term survival in selected patients with solitary liver metastases, the eYcacy of liver resection as a solitary treatment is limited by the number of patients with resectable disease, and even after resection most patients develop recurrent disease in the liver [6] .
Hepatic arterial infusion (HAI) has been used to treat hepatic metastases from any type of cancer (most commonly colorectal), or primary cancers including hepatocellular carcinoma, and biliary tract cancer. The rationale for using HAI is based on the concept that malignant lesions derive most of their blood supply from the hepatic artery, in contrast to normal hepatocytes that are supplied through the portal venous circulation [7] . Cytotoxics administered via the hepatic artery are thought to be extracted during their initial pass through the hepatic parenchyma, therefore maximizing drug concentration in the liver metastases [7] .
In 1989, a controlled clinical trial of HAI consisting of 5-Xuoro-2Ј-deoxyuridine (FUDR) for hepatic metastases from colorectal carcinoma via continuous intraarterial versus continuous intraarterial/intravenous (IV) therapy demonstrated that the combination of intraarterial and IV therapy prevented extrahepatic spread during therapy in most patients, and survival was signiWcantly prolonged in patients with metastatic regression [8] . Results of subsequent clinical trials of intrahepatic therapy were encouraging [9] , and regional adjuvant therapy with FUDR was shown to improve survival in colorectal patients with liver involvement [10, 11] .
The rationale for combining HAI cisplatin and IV liposomal doxorubicin is based on the previously reported encouraging local antitumor activity with intraarterial hepatic infusion/embolization with cisplatin with or without other cytotoxic agents [12] and a 27% partial response rate seen with IV cisplatin and IV liposomal doxorubicin in a phase I study in advanced solid tumors [13] .
Patients and methods
Eligibility criteria included a histologically conWrmed diagnosis of malignancy and liver involvement as the dominant site of metastasis, deWned as hepatic metastases constitutinģ 50% of all tumor burden; Karnofsky performance statuş 60%; and adequate renal (serum creatinine · 1.5 mg/dL or a calculated creatinine clearance >50 mL/min), hepatic (total bilirubin ·1.5 mg/dL, AST ·5 times upper normal reference value, or ALT · 5 times upper normal reference value) and bone marrow function (ANC¸1.5 £ 10 9 /L; PLT¸100 £ 10 9 /L). Female patients with childbearing potential were eligible if they had a negative urine or serum HCG test. Pediatric patients were eligible at the discretion of the primary investigator. Patients were eligible to start therapy if >21 days from day 1 of prior therapy had elapsed, and they had complete recovery from all associated toxicities.
Exclusion criteria included clinical or radiographic evidence of ascites, pregnancy, hypersensitivity to platinum compounds or anthracyclins, inability to complete an informed consent process and adhere to the protocol treatment plan and follow-up requirements, prothrombin time >20 s or INR >2.0, portal vein thrombosis, Grade 2 peripheral neuropathy, or medical history or clinical evidence of congestive heart failure.
All patients signed informed consent forms fully disclosing the investigational nature of the trial prior to enrollment. The study protocol was approved by the M. D. Anderson Cancer Center Institutional Review Board.
Treatment
Patients were admitted for treatment at M. D. Anderson Cancer Center. A hepatic intraarterial catheter was placed by an interventional radiologist using the femoral approach. A 5-French angiographic catheter was utilized to select the celiac and/or superior mesenteric artery, and a co-axial 3 French microcatheter was advanced into the desired hepatic artery. Hepatic artery Xow evaluation was then performed following the injection of 5 mCi Technetium-99 m macroaggregated albumin particles through the HAI catheter used to simulate the distribution of chemotherapeutic agent. The nuclear medicine Xow study was also used to identify any evidence of extra-hepatic Xow to reduce the risk of gastrointestinal complications. The catheter was removed at the end of the cisplatin infusion.
Patients were treated with HAI cisplatin 100-125 mg/m 2 intraarterially in normal saline 250 mL with 3,000 IU heparin intraarterially over 2 h on day 1, followed by liposomal doxorubicin 20-35 mg/m 2 IV mixed in 100 cc 5% dextrose water over 1 h on day 1. Cycles were repeated every 4 weeks. Dose escalation of cisplatin and liposomal doxorubicin is shown in Table 1 . Patients also received dexamethasone 20 mg IV on day 1 prior to chemotherapy followed by 4 mg IV every 12 h for 5 days.
Patient monitoring
Patients were monitored every 4 weeks by physical examination, complete blood counts and diVerential, chemistry laboratory studies, vital signs, periodic serial electrocardiograms, liver function tests and renal function tests everyAll patients had initial tumor staging and assessment after completion of every two cycles of therapy.
Endpoints and statistical considerations
The study was designed using a conventional "3 + 3" study design, followed by an expansion phase composed of 10 patients. Dose-limiting toxicities were assessed during the Wrst cycle and were deWned as follows: any Grade 3-4 adverse event as deWned in the NCI CTC v3.0 (except those that are expected and related to cisplatin, including myelosuppression, alopecia, nausea and vomiting); any Grade 4 hematologic toxicity (as deWned by the NCI CTC) >5 consecutive days or requiring transfusion or growth factor support; and Grade 4 nausea/vomiting > 5 days, and any other Grade 3 non-hematologic toxicity, including symptoms/signs of vascular leak or cytokine release syndrome, or any severe life-threatening complication. The use of growth factors was acceptable during the clinical study.
Best response was assessed by a radiologist from M. D. Anderson Cancer Center starting after 2 cycles of therapy, and after every 2 cycles (1 cycle = 4 weeks) using the RECIST guidelines that were used during the study period [14] . These criteria deWned a partial response (PR) as a 30% decrease in the sum of the longest diameter of target lesions, excluding complete disappearance of disease (CR). Progressive disease was deWned as a ¸20% increase in the sum of the longest diameter of target lesions. Stable disease (SD) was deWned as small changes not meeting the criteria for a PR or progressive disease (PD). Waterfall plot analysis illustrated antitumor activity, if any, as previously described [15] . Responses shown in the waterfall plot were grouped according to standard RECIST criteria.
Survival was measured from start of the treatment on protocol until death from any cause or last follow-up. Progression-free survival was measured from start of treatment on protocol until progression or death, whichever occurred Wrst. Toxicities were assessed using NCI CTC, v. 3.0 [16] . A p value of <0.05 was considered statistically signiWcant.
Statistical analyses were carried out using SAS 9.1 (SAS Institute, Cary, NC, USA) and S-Plus, version 7.0 (Insightful Corp., Seattle, WA, USA).
Results

Demographics
Thirty-two patients were registered on protocol. Two patients were screen failures because of rapid decline of performance status prior to initiation of therapy (n = 1) and baseline ejection fraction of 25-30% (n = 1). Thirty patients were treated. Their median age was 56 (range 15-76). Twenty-Wve women and 5 men were treated. The most common diagnoses were breast cancer (n = 11), colorectal cancer (n = 8) and ocular melanoma (n = 4). One patient had each of one of the following diagnoses: melanoma, gastric cancer, hepatocellular carcinoma, pancreatic cancer, neuroendocrine cancer, adenocystic head and neck cancer and leiomyosarcoma. The median number of prior therapies was 5 (range 1-13). Prior therapies are listed in Table 2 . 
and included Grade 4 neutropenia (2 of 4 patients), and Grade 4 thrombocytopenia (1 of 4 patients).
Toxicity A total of 79 cycles of HAI cisplatin and systemic IV liposomal doxorubicin were administered. The median number of cycles administered per patient was 4 (range 1-6). Toxicities are summarized in Table 4 . Among 30 patients who completed cycle 1, 7 (23%) patients had no toxicity > Grade 1. The most common toxicities were nausea/vomiting (n = 23), fatigue (n = 15) and constipation (n = 13) ( Table 4 ).
Response
Of 30 treated patients, 24 patients reached their Wrst restaging evaluation at 2 months. Six patients were not evaluable for response for the following reasons: 4 withdrew consent after the Wrst (n = 3) or the second (n = 1) cycle of treatment because of toxicities: anorexia and fatigue (n = 1); Grade 2 dehydration and Grade 3 anemia (n = 1); Grade 4 neutropenia and Grade 3 nausea (n = 1); Grade 2 nausea/vomiting, hypertension, and weakness (n = 1), and two patients were lost to follow-up after cycle 1.
Response is shown in Table 5 and Fig. 1 . HAI of cisplatin in combination with systemic liposomal doxorubicin induced a PR in 4 (17%) patients. Tumor size decreased by 38%, 42%, 44% and 51%, for 4, 4, 6 and 4 months, respectively. In addition, seven (29%) patients had SD for at least 4 months. Of the 11 patients with breast cancer, 3 (27%) had a PR and 5 (45%) had SD foŗ 4 months. Of 4 patients with ocular melanoma, 1 had a PR (duration, 4 months) and 1 SD (duration, 4 months). One patient with hepatocellular carcinoma had SD for 4 months. Of 12 evaluable patients treated at the MTD, 2 (17%) had a PR and 5 (42%) had SD. Myalgia/bone pain 8
Neuropathy 6
Abdominal pain Twenty-Wve patients had progressive disease. The median progression-free survival was 3.7 months (95%CI: 2.9-5.0 months; Fig. 1c) . The median progression-free survival in patients with breast cancer was 5.0 months (95%CI: 3.8-10+ months) compared to 2.9 months (95%CI: 2.2-4.9 months) in patients with types of cancer other than breast cancer (p = 0.009).
Discussion
Our study demonstrated that the MTD of HAI cisplatin in combination with systemic liposomal doxorubicin was 100 mg/m 2 and 35 mg/m 2 , respectively. The regimen was well tolerated, and the most common toxicities were nausea/vomiting and fatigue. PRs were noted in 4 (17%) patients (breast cancer, n = 3; ocular melanoma, n = 1) and 29% of patients had SD. At the MTD, the rates of PR and SD were 17 and 42%, respectively.
Hepatotoxicity, previously reported with HAI of chemotherapy, including biliary sclerosis, was reported in earlier trials in 6-25% of patients treated with FUDR [17] but was not observed in our study, probably because of premedication with corticosteroids to prevent toxicity.
Other investigators have demonstrated that HAI of cisplatin and anthracycline-containing regimens has been associated with favorable clinical outcomes in patients with hepatocellular carcinoma [18] [19] [20] [21] [22] [23] , unresectable biliary tract cancer [24] [25] [26] , and metastatic cholangiocarcinoma [27] and advanced gastric cancer [28] . In patients with hepatocellular carcinoma, the reported response rate ranged from 21 to 53%, and the median survival was >1 year [18, 19, [21] [22] [23] . In biliary tract cancer, the response rates were 32-40% [24] [25] [26] [27] , and the median survival ranged from 13 to 18 months [24] [25] [26] [27] . Results of this treatment modality in colorectal cancer were disappointing [29] .
Keeping in mind that in our clinical trial, the median number of prior therapies per patient was 5 therapies, the response rates are encouraging. An intriguing Wnding in our study was that among patients with breast cancer, 3 (27%) patients had a PR and 5 (45%) patients had SD foŗ 4 months. Although the number of patients with breast cancer was small (n = 11), our results suggest that this treatment modality should be further investigated in Phase II clinical trials for patients with advanced breast cancer and dominant liver metastases. Interestingly, antitumor activity was also noted in 2 of 4 patients with ocular melanoma (PR, 1; and SD, 1) and in 1 patient with hepatocellular carcinoma.
In conclusion, the antitumor activity of HAI of cisplatin and systemic liposomal doxorubicin in patients with Table 5 Characteristics of patients treated with hepatic arterial infusion of cisplatin and IV liposomal doxorubicin with stable disease or better and their best response N/A non-applicable, PD progressive disease, PR partial response, PS performance status, SD stable disease a Following discontinuation of HAI of cisplatin and IV liposomal doxorubicin because of poor tolerance, the patient was treated with low-dose vinorelbine and trastuzumab every other week for 5 months. Her neuropathy worsened, and subsequently resection of liver metastases was attempted, but the tumor involved major vascular structures, and therefore resection of metastases was not possible advanced breast cancer, ocular melanoma, and hepatocellular carcinoma with dominant liver metastases suggests that this treatment modality should be further explored, particularly in breast cancer. 
